Francesca Cottini
0000-0001-8676-7840
Publication & Citation Trends
Publications
0 total
Mathematical Modeling to Optimize Receptor Occupancy Assay Development for Isatuximab
Cited by 0
Semantic Scholar
Correction for Hideshima et al., Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma OA
Cited by 0
Semantic Scholar
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. OA
Cited by 45
Semantic Scholar
Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma
Cited by 0
Semantic Scholar
Scientific section designations: Lymphoid Neoplasia Title: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma Short title: TP53RK is a novel therapeutic target in myeloma
Cited by 0
Semantic Scholar
Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma OA
Cited by 55
Semantic Scholar
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma OA
Cited by 119
Semantic Scholar
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. OA
Cited by 104
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(97)
Protein Degradation and Inhibitors
(35)
Peptidase Inhibition and Analysis
(22)
Histone Deacetylase Inhibitors Research
(14)
Ubiquitin and proteasome pathways
(13)
Affiliations
Harvard University
Vita-Salute San Raffaele University
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Policlinico Umberto I
The Ohio State University Wexner Medical Center